Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
TitleBordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Published inMed Microbiol Immunol 2018; 207(1)3-26
PubliekssamenvattingDespite high vaccine coverage, whooping cough caused by Bordetella pertussis remains one of the most common vaccine-preventable diseases worldwide. Introduction of whole-cell pertussis (wP) vaccines in the 1940s and acellular pertussis (aP) vaccines in 1990s reduced the mortality due to pertussis. Despite induction of both antibody and cell-mediated immune (CMI) responses by aP and wP vaccines, there has been resurgence of pertussis in many countries in recent years. Possible reasons hypothesised for resurgence have ranged from incompliance with the recommended vaccination programmes with the currently used aP vaccine to infection with a resurged clinical isolates characterised by mutations in the virulence factors, resulting in antigenic divergence with vaccine strain, and increased production of pertussis toxin, resulting in dampening of immune responses. While use of these vaccines provide varying degrees of protection against whooping cough, protection against infection and transmission appears to be less effective, warranting continuation of efforts in the development of an improved pertussis vaccine formulations capable of achieving this objective. Major approaches currently under evaluation for the development of an improved pertussis vaccine include identification of novel biofilm-associated antigens for incorporation in current aP vaccine formulations, development of live attenuated vaccines and discovery of novel non-toxic adjuvants capable of inducing both antibody and CMI. In this review, the potential roles of different accredited virulence factors, including novel biofilm-associated antigens, of B. pertussis in the evolution, formulation and delivery of improved pertussis vaccines, with potential to block the transmission of whooping cough in the community, are discussed.
- Development of improved vaccines against whooping cough: current status.
- Authors: Marzouqi I, Richmond P, Fry S, Wetherall J, Mukkur T
- Issue date: 2010 Jul
- What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.
- Authors: Bolotin S, Harvill ET, Crowcroft NS
- Issue date: 2015 Nov
- Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
- Authors: Debrie AS, Coutte L, Raze D, Mooi F, Alexander F, Gorringe A, Mielcarek N, Locht C
- Issue date: 2018 Mar 7
- The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development.
- Authors: Preston A
- Issue date: 2016 May 3
- JMM Profile: Bordetella pertussis and whooping cough (pertussis): still a significant cause of infant morbidity and mortality, but vaccine-preventable.
- Authors: Fry NK, Campbell H, Amirthalingam G
- Issue date: 2021 Oct